This episode of The Motley Fool's Market Checkup drills down on the hottest headlines and biggest market movers in the health-care sector.
In this video, health-care analysts David Williamson and Max Macaluso discuss Lexicon Pharmaceuticals' impressive 20% pop after releasing clinical data for LX4211, a type-2 diabetes drug and the company's flagship asset.
Lexicon is targeting a large and lucrative market in diabetes, but that also means it will face stiff competition. Lexicon will have to go toe-to-toe with Johnson & Johnson, which has a similar drug, the recently approved Invokana, on the market, and Forxiga, from a Bristol-Myers Squibb and AstraZeneca partnership, seeking U.S. approval.
David and Max take a closer look at the impact of today's news on Lexicon, the challenges the company will face, and whether investors should hop aboard the stock's bandwagon.
New ways to treat cancer
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.